Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

SANOFI : Former Sanofi employees convicted of bribery in Germany

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/03/2014 | 07:24pm CET

A German court convicted two former employees of Sanofi-Aventis on bribery charges 10 months ago and imposed a fine on the French drugmaker last year, prosecutors said on Monday following a newspaper report.

News of the 28 million euro ($39 million) fine coincides with heightened scrutiny of Big Pharma's sales practices after a bribery scandal in China hit business there last year.

Further investigations are ongoing, a spokesman for prosecutors in the northern German town of Verden said, confirming a report by German daily newspaper Frankfurter Allgemeine Zeitung, but they declined to say whether these were related to Sanofi or to its employees.

The spokesman said an investigation of the former Sanofi employees found that they had made illicit payments to a consultancy advising one of the drugmaker's clients between 2007 and 2010 to win more orders from the client, a pharmaceuticals dealer.

"Sanofi was unfairly given preference because of this," he said.

He declined to provide details on who the client was or which markets it operated in. He also did not name the former Sanofi employees or the consultant.

A court in the town of Winsen handed the two former employees of Sanofi suspended sentences for bribery in business transactions in May 2013, the spokesman said. They both worked with Sanofi's sales force and were not senior managers.

The Winsen court also ordered that punishment be meted out to the owner of the consultancy, but that judgment was not yet final due to a pending complaint against the ruling.

The bribery investigation has not come to light until now because the suspects were sentenced via a simplified legal process that under German law allows courts to try some crimes without a courtroom trial.

The court's ruling also resulted in a 28 million euro fine for Sanofi. A spokeswoman for Sanofi-Aventis Deutschland GmbH confirmed the company had to pay that sum in connection with the case against the two former employees.

"For Sanofi the matter is closed," the spokeswoman said, referring to the Winsen court's rulings. She added the company had cooperated with authorities during the investigation and had since further tightened its compliance system.

Sanofi acquired Aventis in 2004, creating Sanofi-Aventis. In 2011, the company simplified its name to Sanofi.

(Reporting by Maria Sheahan and Frank Siebelt; Additional reporting by Natalie Huet in Paris; Writing by Marilyn Gerlach; editing by Mike Collett-White)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
11/20 Highly Anticipated Agenda Released for Pre-Filled Syringes East Coast 2018
11/18 SANOFI : Uptake Strategies and Sanofi win capability development prize at PMEA
11/16 SANOFI : UGA, Sanofi Pasteur develop new broadly protective vaccines for H3N2 in..
11/16 SANOFI : brings innovative medication to Saudi Arabia
11/15 SANOFI : UGA Research Team Explores Impact of Age on Response to Influenza Vacci..
11/15 DR REDDY LABORATORIES : Launches clofarabine generic injection in us
11/14 SANOFI : Principia agree to develop multiple sclerosis drug candidate
11/14 Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Prov..
11/14 IQVIA : Mylan Launches Generic Clolar for Injection
11/14 SANOFI : Experts clarify myths around diabetes
More news
News from SeekingAlpha
11/20 Sanofi 2017 Q3 - Results - Earnings Call Slides
11/20 Roche Rocks On With More Good News
11/20 Alnylam Sets Its Eyes On The Finish Line
11/16 YOUR DAILY PHARMA SCOOP : A Look At Sanofi, Ultragenyx Gets FDA Nod, Capricor Tu..
11/15 SANOFI Q3 2017 : Weak Signals
Financials (€)
Sales 2017 35 912 M
EBIT 2017 9 371 M
Net income 2017 7 904 M
Debt 2017 4 658 M
Yield 2017 4,00%
P/E ratio 2017 12,20
P/E ratio 2018 16,26
EV / Sales 2017 2,79x
EV / Sales 2018 2,74x
Capitalization 95 682 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 85,2 €
Spread / Average Target 12%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-1.91%112 335
JOHNSON & JOHNSON19.78%370 552
NOVARTIS11.20%220 012
ROCHE HOLDING LTD.-1.55%212 913
PFIZER8.90%210 711
MERCK AND COMPANY-6.23%147 550